白蛋白结合紫杉醇联合抗pd -1抗体治疗胰管腺癌的疗效和安全性

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Wenjing Hao, Yunxia Wang, Jun Zhang, Weimin Cai
{"title":"白蛋白结合紫杉醇联合抗pd -1抗体治疗胰管腺癌的疗效和安全性","authors":"Wenjing Hao,&nbsp;Yunxia Wang,&nbsp;Jun Zhang,&nbsp;Weimin Cai","doi":"10.1002/adtp.202500075","DOIUrl":null,"url":null,"abstract":"<p>Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with limited response to chemotherapy and immune checkpoint inhibitors (ICIs). This study evaluates the efficacy and safety of combining Albumin-Bound Paclitaxel (nab-PTX) with an anti-PD-1 antibody and aims to identify potential biomarkers to optimize therapeutic outcomes. The murine model of PDAC is established by subcutaneously injecting the murine pancreatic cancer cell line Panc02 into C57BL/6J mice. The mice are treated with either an anti-PD-1 antibody, nab-PTX, or nab-PTX plus anti-PD-1 antibody, with untreated mice serving as the control. Tumor growth, immune cell infiltration, cytokine levels, overall survival, organ damage, and gene expression profiles are analyzed. The combination therapy shows superior efficacy compared to nab-PTX and non-inferior efficacy compared to the anti-PD-1 antibody. Moreover, this strategy significantly reduces the risk of irAEs and hyperprogression caused by the anti-PD-1 antibody. In addition, screening identifies <i>WNT9a</i> as a potential gene associated with improved efficacy and <i>ATF3</i> with enhanced safety, providing valuable insights for optimizing therapeutic strategies in PDAC.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 9","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of The Albumin-Bound Paclitaxel Combined with Anti-PD-1 Antibody in Pancreatic Ductal Adenocarcinoma\",\"authors\":\"Wenjing Hao,&nbsp;Yunxia Wang,&nbsp;Jun Zhang,&nbsp;Weimin Cai\",\"doi\":\"10.1002/adtp.202500075\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with limited response to chemotherapy and immune checkpoint inhibitors (ICIs). This study evaluates the efficacy and safety of combining Albumin-Bound Paclitaxel (nab-PTX) with an anti-PD-1 antibody and aims to identify potential biomarkers to optimize therapeutic outcomes. The murine model of PDAC is established by subcutaneously injecting the murine pancreatic cancer cell line Panc02 into C57BL/6J mice. The mice are treated with either an anti-PD-1 antibody, nab-PTX, or nab-PTX plus anti-PD-1 antibody, with untreated mice serving as the control. Tumor growth, immune cell infiltration, cytokine levels, overall survival, organ damage, and gene expression profiles are analyzed. The combination therapy shows superior efficacy compared to nab-PTX and non-inferior efficacy compared to the anti-PD-1 antibody. Moreover, this strategy significantly reduces the risk of irAEs and hyperprogression caused by the anti-PD-1 antibody. In addition, screening identifies <i>WNT9a</i> as a potential gene associated with improved efficacy and <i>ATF3</i> with enhanced safety, providing valuable insights for optimizing therapeutic strategies in PDAC.</p>\",\"PeriodicalId\":7284,\"journal\":{\"name\":\"Advanced Therapeutics\",\"volume\":\"8 9\",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advanced Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://advanced.onlinelibrary.wiley.com/doi/10.1002/adtp.202500075\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://advanced.onlinelibrary.wiley.com/doi/10.1002/adtp.202500075","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

胰腺导管腺癌(PDAC)是一种对化疗和免疫检查点抑制剂(ICIs)反应有限的高致死性恶性肿瘤。本研究评估白蛋白结合紫杉醇(nab-PTX)联合抗pd -1抗体的有效性和安全性,旨在鉴定潜在的生物标志物以优化治疗结果。采用小鼠胰腺癌细胞系Panc02皮下注射C57BL/6J小鼠,建立小鼠PDAC模型。用抗pd -1抗体nab-PTX或nab-PTX加抗pd -1抗体治疗小鼠,未治疗的小鼠作为对照。分析肿瘤生长、免疫细胞浸润、细胞因子水平、总体生存、器官损伤和基因表达谱。联合治疗效果优于nab-PTX,优于抗pd -1抗体。此外,该策略显著降低了抗pd -1抗体引起的irae和超进展的风险。此外,筛选发现WNT9a是与改善疗效和增强安全性的ATF3相关的潜在基因,为优化PDAC的治疗策略提供了有价值的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Efficacy and Safety of The Albumin-Bound Paclitaxel Combined with Anti-PD-1 Antibody in Pancreatic Ductal Adenocarcinoma

Efficacy and Safety of The Albumin-Bound Paclitaxel Combined with Anti-PD-1 Antibody in Pancreatic Ductal Adenocarcinoma

Efficacy and Safety of The Albumin-Bound Paclitaxel Combined with Anti-PD-1 Antibody in Pancreatic Ductal Adenocarcinoma

Efficacy and Safety of The Albumin-Bound Paclitaxel Combined with Anti-PD-1 Antibody in Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with limited response to chemotherapy and immune checkpoint inhibitors (ICIs). This study evaluates the efficacy and safety of combining Albumin-Bound Paclitaxel (nab-PTX) with an anti-PD-1 antibody and aims to identify potential biomarkers to optimize therapeutic outcomes. The murine model of PDAC is established by subcutaneously injecting the murine pancreatic cancer cell line Panc02 into C57BL/6J mice. The mice are treated with either an anti-PD-1 antibody, nab-PTX, or nab-PTX plus anti-PD-1 antibody, with untreated mice serving as the control. Tumor growth, immune cell infiltration, cytokine levels, overall survival, organ damage, and gene expression profiles are analyzed. The combination therapy shows superior efficacy compared to nab-PTX and non-inferior efficacy compared to the anti-PD-1 antibody. Moreover, this strategy significantly reduces the risk of irAEs and hyperprogression caused by the anti-PD-1 antibody. In addition, screening identifies WNT9a as a potential gene associated with improved efficacy and ATF3 with enhanced safety, providing valuable insights for optimizing therapeutic strategies in PDAC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advanced Therapeutics
Advanced Therapeutics Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
7.10
自引率
2.20%
发文量
130
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信